Which Coagulation Tests Diagnose a Clotting Disorder and What the Results Mean

The nurse presses a cotton ball onto the crook of your elbow and asks you to keep it there. Two minutes later the bleeding has stopped, which feels ordinary until you remember why you are here: the nosebleeds that last twenty minutes, the bruise that appeared on your thigh with no story attached, the dentist who raised an eyebrow after a routine extraction. Somewhere behind the wall, a light-blue-topped tube of your blood is being spun, warmed and timed to the second.

Coagulation tests explained plainly are not mysterious. They are stopwatches. Each one measures how many seconds it takes plasma to form a clot when a specific trigger is added, and each trigger probes a different stretch of the clotting pathway. Reading the numbers well means knowing which stretch a test can see, which it cannot, and why a perfectly normal screen sometimes coexists with a real bleeding disorder.

This explainer walks through the standard panel, the follow-up tests, what the results tend to mean, and where the honest limits lie.

Coagulation tests explained: what a panel actually measures

Coagulation is the process by which liquid blood turns into a gel-like plug at a site of injury. It runs on two systems working at once. Platelets, the tiny cell fragments that stick to damaged vessel walls, form the first loose patch. Clotting factors, a chain of roughly a dozen proteins made mostly in the liver, then generate thrombin, the enzyme that converts fibrinogen into strands of fibrin that knit the platelet plug into something sturdy.

Laboratory clotting tests isolate the protein half of that system. A sample is drawn into a tube containing citrate, a chemical that binds calcium and stops the blood from clotting in transit. In the lab, the plasma is separated, warmed to body temperature, and calcium is added back along with a chosen trigger. An optical or mechanical sensor watches for the moment the plasma turns turbid or the sample resists a moving probe, and the machine records the seconds.

Different triggers illuminate different parts of the pathway. Tissue factor with phospholipid starts the route measured by prothrombin time. A contact activator such as silica or kaolin starts the route measured by the activated partial thromboplastin time. Thrombin added directly measures fibrinogen. Because each test depends on several factors at once, a prolonged result says something is short or blocked somewhere along that stretch, not which factor is responsible. Pinning down the culprit takes the second-line tests described later.

One point matters above the rest: these tests were designed to find deficiencies in clotting proteins and to monitor certain anticoagulant medicines. They were not designed to measure how well platelets work, and they cannot see most inherited tendencies toward excess clotting. Knowing that boundary saves a great deal of confusion, according to the test overviews published by MedlinePlus.

Why would a doctor order a coagulation test?

The most common reason has nothing to do with a suspected disorder. Surgeons and anesthetists often ask for a prothrombin time and partial thromboplastin time before an operation, biopsy or spinal procedure, because a hidden clotting problem discovered on the table is far harder to manage than one discovered in clinic. Whether routine preoperative testing is useful in people with no bleeding history is debated in the surgical literature; many teams now reserve it for those with symptoms, liver disease, or a relevant medication.

The second reason is monitoring. People taking warfarin, a vitamin K antagonist, need regular INR checks because the drug’s effect drifts with diet, illness and other medicines. Unfractionated heparin given by infusion is typically monitored with the aPTT. Mayo Clinic notes that the INR is the standard way clinicians adjust warfarin, and that targets vary by the condition being treated.

The third reason is the one that brings most readers here: unexplained bleeding. Heavy menstrual periods since the teens, nosebleeds that need medical attention, gum bleeding, bruises larger than a coin appearing without injury, prolonged bleeding after dental work, or a family history of a bleeding disorder all prompt a screen.

Fourth, clotting tests help assess organ function and acute illness. The liver makes most clotting factors, so a rising PT can track worsening liver disease. In sepsis, severe trauma or some cancers, the body can consume factors and platelets faster than it replaces them, a state called disseminated intravascular coagulation, or DIC, which shows up as prolonged times, low fibrinogen and high D-dimer together.

Finally, a blood clot in a leg vein or lung sometimes triggers a different kind of testing, for inherited or acquired thrombophilia, which is a tendency toward clotting. Those tests are separate from the bleeding screen and are covered below, because they are often ordered at the wrong moment.

PT, INR and PTT meaning: the three numbers on almost every report

Prothrombin time, or PT, measures how many seconds plasma takes to clot after tissue factor is added. It is sensitive to factors VII, X, V, II and fibrinogen, the so-called extrinsic and common pathways. MedlinePlus explains that laboratories differ in the reagents they use, so a PT of thirteen seconds in one hospital is not directly comparable with the same number elsewhere.

That problem is why the INR exists. The International Normalized Ratio is a mathematical correction that converts a PT into a figure that means the same thing in any laboratory. An INR of 1.0 represents a typical person not taking an anticoagulant. Higher numbers mean slower clotting. The INR was built specifically for warfarin monitoring; for most treatment indications the usual therapeutic range runs from 2.0 to 3.0, per Mayo Clinic, although the treating clinician sets the individual target and some conditions call for a different range.

Partial thromboplastin time, usually reported as activated PTT or aPTT, uses a contact activator instead of tissue factor. It is sensitive to factors XII, XI, IX and VIII, the intrinsic pathway, plus the shared common pathway. Hemophilia A and B, which are deficiencies of factors VIII and IX, prolong the aPTT while leaving the PT normal. Unfractionated heparin prolongs it too.

Reading the two together is where the logic lives. A long PT with a normal aPTT points toward factor VII or early warfarin effect. A long aPTT with a normal PT points toward the intrinsic factors, heparin or an inhibitor. Both prolonged suggests something in the shared pathway: low fibrinogen, a factor X, V or II problem, liver disease, vitamin K deficiency, or DIC.

Reference ranges are printed beside every result and are the correct comparison. The words normal and abnormal on a report are a starting point for a conversation, not a diagnosis.

What a prolonged PT or high INR usually points to

Think of the PT as the liver’s report card with a vitamin K footnote. Four of the factors it depends on, II, VII, IX and X, need vitamin K to become active. Factor VII has the shortest lifespan of the group, a matter of hours, so anything that interrupts vitamin K supply or liver synthesis shows up in the PT first.

Warfarin is the classic example. It blocks the enzyme that recycles vitamin K, so newly made factors are ineffective. Because existing factors have to wear out before the effect appears, the INR typically takes several days to climb after starting the medicine, which is why clinicians check it repeatedly early on rather than once. That timeline is a property of the biology, not of any particular prescription, and dosing decisions belong entirely to the prescribing team.

Vitamin K deficiency without medication happens in people who cannot absorb fat properly, in prolonged poor intake, and after long courses of broad-spectrum antibiotics that reduce gut bacteria producing the vitamin. Newborns are born with low stores, which is why vitamin K is offered at birth.

Liver disease prolongs the PT because damaged hepatocytes make fewer factors. In advanced cirrhosis the PT can be substantially prolonged, yet paradoxically such patients can still form dangerous clots because the liver also makes the natural anticoagulant proteins. A high INR in liver disease does not translate into the same bleeding protection it implies in someone on warfarin, a nuance that often surprises people reading their own results.

Isolated factor VII deficiency is rare and inherited. Direct oral anticoagulants that block factor Xa can nudge the PT upward inconsistently, and dabigatran, a direct thrombin inhibitor, affects the aPTT and thrombin time more reliably than the PT. Neither class is monitored with the INR, which is one reason a normal INR does not confirm that a modern anticoagulant is absent or working. MedlinePlus covers the PT and INR in detail for readers who want the laboratory perspective.

Prolonged aPTT causes: from heparin to hemophilia

A long aPTT is the result most likely to lead somewhere important, and also the one most likely to be an artefact. The list of causes sorts into three buckets.

The first bucket is medication and sampling. Unfractionated heparin prolongs the aPTT by design. A sample drawn from an arm with a heparin infusion running, or through a line flushed with heparin, can look alarming and mean nothing. An underfilled tube changes the citrate-to-blood ratio and lengthens the time. A very high hematocrit does the same. Laboratories reject obviously underfilled tubes, but borderline ones slip through, so an unexpected result is often simply redrawn.

The second bucket is a missing factor. Hemophilia A, a deficiency of factor VIII, and hemophilia B, a deficiency of factor IX, are inherited on the X chromosome and, as the NHS describes, mostly affect males, although females who carry the gene can have reduced levels and bleed more than expected. Factor XI deficiency is milder and more common in some populations. Factor XII deficiency prolongs the aPTT sharply yet does not cause bleeding at all, a reminder that a test-tube result and a body are not the same thing.

The third bucket is an inhibitor. Lupus anticoagulant is an antibody that interferes with the phospholipid in the test reagent. Despite its name it is associated with clotting rather than bleeding and occurs in people with or without lupus. Acquired hemophilia, in which the immune system attacks factor VIII, is rare but serious and tends to appear in older adults or after pregnancy.

Distinguishing bucket two from bucket three is the job of the mixing study, described in the next section. Von Willebrand disease can also prolong the aPTT modestly because von Willebrand factor carries factor VIII, but many people with the condition have an entirely normal screen. MedlinePlus has a plain-language overview of the PTT test and its common causes.

Beyond the basic screen: fibrinogen, D-dimer, platelets, mixing studies and factor assays

The two-test screen answers the question is something wrong along these pathways. The tests that follow answer what, exactly.

Fibrinogen is the protein that thrombin converts into the fibrin mesh. Measuring it directly matters because both the PT and aPTT only lengthen when fibrinogen is quite low. It rises with inflammation and pregnancy and falls in DIC, severe liver failure, massive hemorrhage and a few inherited disorders.

D-dimer is a fragment released when a fibrin clot is broken down. Its presence means clots have formed and are being dissolved somewhere, which happens after surgery, in infection, in pregnancy and with age, as well as in venous thrombosis. Clinicians use a negative result in a low-risk person to make a leg or lung clot unlikely; a positive result alone does not diagnose one and usually leads to imaging.

A platelet count is part of every workup because low platelets cause bleeding that the PT and aPTT cannot detect. When counts are normal but platelet-type bleeding is suspected, platelet function tests or aggregation studies may follow.

The mixing study takes a prolonged sample and combines it in equal parts with normal plasma. If the time corrects, the patient’s plasma lacked a factor and the normal plasma supplied it. If it stays prolonged, something in the patient’s plasma is actively inhibiting the reaction, pointing toward lupus anticoagulant or an acquired factor inhibitor.

Factor assays then measure individual proteins as a percentage of normal activity. MedlinePlus explains that these tests identify which specific factor is low and how severely, which is what turns a suspicion of hemophilia into a named diagnosis with a severity grade. Von Willebrand testing is its own family of assays measuring the protein’s quantity and its ability to bind platelets, often repeated because levels fluctuate with stress, illness and hormonal state.

Coagulation tests explained in one table

Laboratory reports rarely come with a map. The table below lays out what each common test looks at, what tends to push it out of range, and the blind spots worth remembering. Reference intervals are deliberately omitted because they belong to the laboratory that ran your sample, as MedlinePlus emphasizes.

Test	What it measures	Common reasons for an abnormal result	What it cannot see
Prothrombin time (PT) and INR	Seconds to clot after tissue factor; extrinsic and common pathways (VII, X, V, II, fibrinogen)	Warfarin, vitamin K deficiency, liver disease, DIC, factor VII deficiency	Factors VIII, IX, XI; platelet problems; most direct oral anticoagulants
Activated partial thromboplastin time (aPTT)	Seconds to clot after contact activation; intrinsic and common pathways	Heparin, hemophilia A or B, factor XI or XII deficiency, lupus anticoagulant, von Willebrand disease (sometimes)	Factor VII; mild von Willebrand disease; platelet function
Fibrinogen	Amount of clottable fibrinogen protein	Low in DIC, liver failure, major bleeding, inherited deficiency; high in inflammation, pregnancy	Whether the protein works normally in rare qualitative disorders
D-dimer	Breakdown products of cross-linked fibrin	Venous thrombosis, DIC, surgery, infection, pregnancy, older age	Where a clot is, or whether one is present when positive
Platelet count	Number of platelets per volume of blood	Low in immune thrombocytopenia, marrow disorders, medicines, DIC, liver disease	How well platelets function
Mixing study	Whether a prolonged time corrects with normal plasma	Corrects in factor deficiency; fails to correct with an inhibitor	Which factor or inhibitor is responsible
Factor assays and von Willebrand studies	Activity of a single named factor or von Willebrand factor	Hemophilia A and B, von Willebrand disease, rare factor deficiencies	Anything outside the factor tested; levels vary day to day

Reading down the last column is the most useful habit a patient can build. Almost every diagnostic misstep in this field comes from asking a test to answer a question it was never built for.

What is the most common bleeding disorder? Von Willebrand disease and the limits of screening

Ask most people to name a bleeding disorder and they say hemophilia. Ask a hematologist which one they diagnose most often and the answer is von Willebrand disease. The CDC estimates it affects up to one percent of the population, which makes it far more common than hemophilia, and it affects women and men equally, although women tend to notice it earlier because of menstruation and childbirth.

Von Willebrand factor is a large protein with two jobs: it glues platelets to the wall of an injured vessel, and it carries factor VIII through the bloodstream, protecting it from breakdown. When the protein is scarce or malformed, the first platelet plug forms poorly. Bleeding tends to be mucosal, meaning nosebleeds, gum bleeding, heavy periods and prolonged oozing after cuts or dental work, rather than the deep joint and muscle bleeds typical of severe hemophilia.

Here is the uncomfortable truth about screening. The PT is normal in von Willebrand disease. The aPTT is normal in many cases too, because factor VIII is only modestly reduced. The platelet count is normal. A person can walk out of a preoperative clinic with a clean panel and still have the most common bleeding disorder there is. Diagnosis requires specific assays of von Willebrand factor quantity and function, often repeated, since levels rise with stress, exercise, pregnancy and estrogen-containing contraception and can temporarily mask a deficiency.

That is why a structured bleeding history carries as much weight as the tubes. Clinicians use standardized questionnaires that score the severity and number of bleeding episodes, and a high score with a normal screen is a legitimate reason to test further rather than to reassure and stop.

Hemophilia, by contrast, is rare and inherited, and the NHS describes a spectrum from mild disease noticed only after surgery to severe disease with spontaneous bleeding into joints. Both conditions are managed by specialist teams, and the specifics of any treatment plan rest with them.

Who is usually tested, and who is usually asked to wait

Testing is most informative when the question is clear. People with a personal or family history of abnormal bleeding, those about to have surgery where bleeding would be hard to control, anyone on warfarin or intravenous heparin, and people with liver disease or suspected DIC are the groups for whom a coagulation panel changes decisions.

Children with easy bruising, adolescents with heavy periods from the first cycle, and adults with a new, unexplained bleeding pattern are appropriate candidates for a bleeding workup. Because the results shape what happens at the dentist and in the delivery room for the rest of a person’s life, hematologists often prefer to complete the workup thoroughly rather than quickly.

Some people are asked to wait, and the reasons are practical rather than dismissive. Thrombophilia testing after a blood clot is the clearest example. Several of the natural anticoagulant proteins, protein C, protein S and antithrombin, are consumed during an acute clot and altered by anticoagulant medicines, so testing in the first weeks or while on treatment produces misleading lows. Lupus anticoagulant testing is likewise unreliable on many anticoagulants. Guideline groups generally advise deferring these tests until treatment decisions would actually change based on the result, and interpreting them only in specialist hands.

Von Willebrand testing during pregnancy, acute illness, or while taking estrogen can miss the diagnosis because levels are temporarily raised; a clinician may schedule the test for a quieter time or repeat it.

Timing within the day matters less than people expect. Fasting is not required for a standard coagulation panel, according to MedlinePlus, though it may be if other tests are drawn at the same time. What does matter is telling the phlebotomist about every anticoagulant, antiplatelet medicine and supplement you take, and when the last dose was, because those details determine whether an abnormal result is a finding or a footnote.

What happens on the day and how long coagulation tests take

The procedure itself is a routine venipuncture. A tourniquet goes on, a vein in the arm is cleaned, and blood flows into a tube with a light blue top containing sodium citrate. The tube must be filled to its line and gently inverted several times; the phlebotomist is not being fussy, since the ratio of blood to citrate is what keeps the result valid. MedlinePlus describes the draw as taking under five minutes with, at most, a brief sting and a small bruise.

If a heparin infusion is running, blood is taken from the opposite arm. If you have a bleeding tendency, pressure is held a little longer and you may be asked to keep the arm straight for a few minutes rather than bending it, which reduces bruising.

Turnaround depends on which test was ordered. PT, INR, aPTT, fibrinogen and platelet count run on automated analyzers in most hospital laboratories, and many report them within a few hours; emergency departments often see them faster. Point-of-care INR devices used in anticoagulation clinics give a reading from a fingerstick in about a minute, though clinicians may confirm unexpected values with a venous sample.

Mixing studies, factor assays and von Willebrand panels are more labor-intensive and may be sent to a regional or reference laboratory. Results in days is common; several weeks is not unusual for specialized genetic or platelet function testing. Your team should be able to tell you which category your tests fall into when the sample is taken.

One practical note: laboratories reject samples that are clotted, underfilled or hemolyzed, meaning red cells burst during a difficult draw. A phone call asking you to come back for a redraw is usually a quality control, not a sign that something worrying was found.

What the following days and weeks usually look like

For most people the story ends quickly. A normal preoperative screen is filed, surgery proceeds, and the tubes are never mentioned again. A routine INR within target leads to a note in the anticoagulation record and a date for the next check, spaced according to how stable readings have been; Mayo Clinic notes that people newly started on warfarin are checked frequently and that intervals lengthen once results settle.

An unexpected abnormal result usually triggers a repeat first. Sampling problems account for a meaningful share of isolated prolonged times, so a second draw, ideally from a good vein with a full tube, is standard before anyone reaches for a diagnosis. If the repeat is also prolonged, the next step is often a mixing study and targeted factor levels, ordered by the requesting clinician or by a hematologist to whom you are referred.

Referral to hematology generally means a longer appointment than you may expect. The consultant will take a detailed bleeding history covering childhood, dental work, surgery, menstruation and childbirth, ask about relatives, review medicines and supplements, and examine you for bruising and joint changes. Blood may be drawn again for a full panel including von Willebrand studies, sometimes on more than one occasion to account for day-to-day variation.

Results arrive in stages. The basic repeat often comes back within days; factor assays and von Willebrand studies within one to a few weeks; genetic confirmation, where it is sought, longer still. Between visits you may be asked to avoid aspirin and anti-inflammatory painkillers, which impair platelet function, and to carry a note for any dentist or surgeon until the picture is clear. Those are typical patterns rather than promises, and the sequence is set by the treating team.

If a diagnosis is confirmed, the following weeks usually involve a management plan for injuries, procedures and, where relevant, pregnancy, together with information for family members who may wish to be tested.

What people often get wrong about clotting tests

The first myth is that a normal coagulation panel means you cannot have a bleeding disorder. Von Willebrand disease, platelet function disorders and mild factor deficiencies routinely produce normal screens. A thorough bleeding history outranks a normal PT and aPTT.

The second is the mirror image: an abnormal result means you have a disorder. Prolonged times are frequently caused by heparin contamination, an underfilled tube, a slow draw, or a medicine you forgot to mention. Factor XII deficiency prolongs the aPTT dramatically and causes no bleeding whatsoever. Lupus anticoagulant prolongs it and is associated with clots, not bleeds.

Third, people assume a high INR always means thin blood in the everyday sense. In warfarin therapy that inference is reasonable and is the entire point of the test. In liver disease it is not; the same liver that fails to make clotting factors also fails to make anticoagulant proteins, and such patients can clot and bleed at the same time.

Fourth, a normal INR is taken as proof that a newer anticoagulant is absent or ineffective. Factor Xa inhibitors and direct thrombin inhibitors were designed not to need INR monitoring, and the INR barely moves with several of them. Their presence is assessed differently, by the prescribing team.

Fifth, D-dimer is misunderstood as a clot detector. A raised level is common after surgery, in infection, in pregnancy and with advancing age. Its real value is that a low level in someone at low clinical risk makes a clot unlikely and can spare a scan.

Sixth, people believe supplements are irrelevant. Fish oil, high-dose vitamin E, garlic and ginkgo have been reported to affect platelets or interact with anticoagulants, and cranberry and some herbal products can interact with warfarin. The NIH Office of Dietary Supplements maintains fact sheets on several of these. Mention everything you take; the laboratory cannot see it.

Questions to ask your care team

A coagulation result rarely explains itself, and the appointment in which it is discussed can be brief. Arriving with specific questions turns a printout into a plan. Consider asking:

• Which part of the clotting process did this test look at, and what would a problem there mean for me day to day?
• Could this result be caused by a medicine, a supplement, or how the sample was taken, and should it be repeated before anything else?
• Does my bleeding history fit this result, or does the history alone justify further testing even though the screen is normal?
• What is the next test, why that one, and roughly how long until results are expected?
• Should I avoid aspirin, anti-inflammatory painkillers or any supplement while this is being worked out?
• Do I need a note for my dentist or for any procedure already booked?
• If I am on an anticoagulant, what INR or other target has been set for me, and who do I contact if I miss a check or have unusual bleeding?
• Is this something that could run in my family, and would relatives benefit from testing?
• Will pregnancy, contraception or hormone therapy change how these tests should be interpreted or timed?
• Who owns this result, meaning which clinician is responsible for following it up, and how will I be told?

Two further questions are worth keeping in reserve. If a thrombophilia panel is being proposed after a clot, ask what decision it would change; guideline groups are increasingly cautious about testing that does not alter management. And if a diagnosis such as von Willebrand disease or a factor deficiency is confirmed, ask whether you should be registered with a specialist center, since these conditions are managed by hematology teams with protocols for surgery, injury and childbirth. The answers, and every treatment choice that follows, remain with your treating clinicians.

When to call your doctor

Most coagulation results can wait for a scheduled conversation. Some symptoms cannot, whether or not you have had a test recently.

Seek urgent medical care, by emergency services if needed, for bleeding that will not stop after ten minutes of firm pressure; vomiting blood or material that looks like coffee grounds; black, tarry or bloody stools; coughing up blood; a nosebleed lasting more than twenty minutes despite pinching the soft part of the nose; a sudden severe headache, confusion, weakness on one side, slurred speech or a seizure, particularly if you take an anticoagulant or have a known bleeding disorder; a large, rapidly expanding bruise or a swollen, painful joint after minor or no injury; or heavy vaginal bleeding soaking a pad an hour for several hours. Any significant head injury while on an anticoagulant warrants assessment even if you feel well.

Call your care team the same day for new, widespread pinpoint red or purple spots on the skin, gum bleeding without brushing, blood in urine, bruising that appears without explanation, an INR reading far above or below your usual range, or a missed anticoagulant dose you are unsure how to handle. Do not adjust or stop a prescribed medicine on the strength of a test result; the prescribing clinician makes that call.

Seek urgent assessment as well for the signs of a clot rather than a bleed: one calf swollen, warm and painful compared with the other, or sudden breathlessness, chest pain that worsens on breathing in, a racing heart or fainting. Those symptoms need imaging, not a laboratory test, and they need it promptly. The general guidance on when to seek care for abnormal bleeding is summarized by MedlinePlus and the NHS, and your own team may give you a more specific plan based on your results.

Frequently asked questions

What does PT, INR and PTT test for?

PT measures seconds to clot after tissue factor is added and reflects factors VII, X, V, II and fibrinogen. INR is the PT converted to a standardized figure used to monitor warfarin. PTT, or aPTT, uses a contact activator and reflects factors XII, XI, IX and VIII plus the shared pathway, and is prolonged in hemophilia and with heparin. Together they map which stretch of the clotting cascade may be affected.

What is the most common bleeding disorder?

Von Willebrand disease is the most common inherited bleeding disorder, estimated by the CDC to affect up to one percent of the population and occurring equally in women and men. It causes mucosal bleeding such as nosebleeds, heavy periods and prolonged bleeding after dental work. Standard screening tests are often normal, so diagnosis requires specific von Willebrand factor assays, sometimes repeated because levels vary.

Why would a doctor order a coagulation test?

Common reasons include checking clotting before surgery or a procedure, monitoring warfarin with the INR or intravenous heparin with the aPTT, investigating unexplained bleeding or bruising, assessing liver function, and evaluating acute conditions such as sepsis or suspected DIC. A family history of a bleeding disorder or heavy menstrual bleeding since adolescence also prompts testing. The specific tests chosen depend on the question being asked.

How long do coagulation tests take?

The blood draw takes under five minutes. Routine PT, INR, aPTT, fibrinogen and platelet counts run on automated analyzers and are often reported within hours in hospital laboratories; fingerstick INR devices in anticoagulation clinics read in about a minute. Specialized tests such as mixing studies, factor assays and von Willebrand panels may be sent to reference laboratories and typically take days to a few weeks. Your team can say which applies.

What is a coagulation panel blood test?

A coagulation panel is a group of tests, usually PT with INR, aPTT, fibrinogen and a platelet count, sometimes with D-dimer, drawn into a citrate tube and timed in the laboratory. It screens the clotting factor pathways and platelet numbers. It does not assess platelet function or most inherited clotting tendencies, so a normal panel does not exclude every bleeding or clotting disorder.

What are the main prolonged aPTT causes?

Heparin exposure, including contamination from an intravenous line, is the most frequent cause, followed by sampling problems such as an underfilled tube. True causes include hemophilia A or B, factor XI or XII deficiency, von Willebrand disease, lupus anticoagulant, and acquired factor inhibitors. A mixing study distinguishes a missing factor from an inhibitor, and factor assays then identify the specific protein involved.

Do I need to fast before a clotting test?

No fasting is required for a standard coagulation panel, according to MedlinePlus, although you may be asked to fast if other blood tests are drawn at the same visit. What matters more is telling the phlebotomist and clinician about every anticoagulant, antiplatelet medicine and supplement you take and when the last dose was, since these directly influence the results and how they are interpreted.

Can a normal coagulation test miss a bleeding disorder?

Yes. Von Willebrand disease, platelet function disorders and mild factor deficiencies commonly produce normal PT, aPTT and platelet counts. Clinicians therefore use structured bleeding history questionnaires alongside the laboratory screen, and a strong history with normal results is a valid reason for specialized testing such as von Willebrand assays or platelet function studies rather than reassurance alone.

What does a high INR mean if I am not on warfarin?

In someone not taking a vitamin K antagonist, a raised INR usually points to liver disease, vitamin K deficiency, DIC, or a rare factor deficiency, and occasionally to a sampling artefact. It does not carry the same bleeding implication as in warfarin therapy, particularly in cirrhosis, where clotting and anticoagulant proteins fall together. The result should be repeated and interpreted by the treating clinician alongside liver tests.

When should thrombophilia tests be done after a blood clot?

Usually not during the acute clot or while on anticoagulant treatment. Protein C, protein S and antithrombin levels fall during active clotting and are altered by anticoagulants, and lupus anticoagulant testing is unreliable on many of them. Specialists generally defer testing until it would change a decision about treatment duration or family screening, and interpret results in the context of the person’s history.

References

• MedlinePlus: Prothrombin Time Test and INR (PT/INR)
• MedlinePlus: Partial Thromboplastin Time (PTT) Test
• MedlinePlus: Coagulation Factor Tests
• CDC: About Von Willebrand Disease

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.